

BIO035C – Table of Contents

INTRODUCTION	XIX
STUDY GOALS AND OBJECTIVES	XIX
REASONS FOR DOING THE STUDY	XIX
SCOPE OF REPORT	XIX
INTENDED AUDIENCE	XX
INFORMATION SOURCES	XX
ANALYST CREDENTIALS	XXI
RELATED REPORTS	XXI
BCC ONLINE SERVICES	XXI
DISCLAIMER	XXII
SUMMARY	XXIII
SUMMARY TABLE U.S. MARKET FOR STEM CELLS IN REGENERATIVE MEDICINE REVENUE, THROUGH 2012 (\$ MILLIONS)	XXIV
SUMMARY FIGURE U.S. MARKET FOR STEM CELLS IN REGENERATIVE MEDICINE REVENUE, 2005-2012 (\$ MILLIONS)	XXIV
OVERVIEW	1
HISTORICAL REVIEW OF STEM CELL BIOLOGY	1
HISTORY OF STEM CELL BIOLOGY	1
EARLY OBSERVATION AND CLASSIFICATIONS	1
STEM CELL CLASSIFICATION	2
Derivation of Human Tissue Types during Development from Embryonic Stem Cells	2
TABLE 1 DERIVATION OF HUMAN TISSUE TYPES DURING DEVELOPMENT	3
FIGURE 1 FLOW DIAGRAM OF HUMAN DEVELOPMENT PROCESS	4
Derivation of Human Tissue Following Maturation from Adult Stem Cells	4
STEM CELL CONCEPTS IN HEALTH CARE	5
INITIAL STEM CELL ISOLATION AND CHARACTERIZATION	5
Initial Stem Cell Isolation ...(Continued)	6
EARLY CELL-BASED THERAPEUTICS	7
Xeno Transplants	7
Blood Transfusions and Bone Marrow Transplantation	8
AREAS OF HEALTH CARE NEED AND STEM CELLS	9
DISEASE- AND DEGENERATION-RELATED HEALTH CARE NEED	9
Disease- and Degeneration-...(Continued)	10
ORGAN TRANSPLANTATION-RELATED HEALTH CARE NEED	11
CANCER- AND GENETIC DISORDER-RELATED HEALTH CARE NEED	11
INFECTIOUS DISEASE-RELATED HEALTH CARE NEED	12
HEALTH CARE NEED AND COSTS	12
Health Care Need and Costs (Continued)	13
CURRENT STATE OF REGENERATIVE MEDICINE	14
STEM CELL CLASSIFICATION BASED ON SOURCE	14
Embryonic Stem Cells	15
Adult (and Progenitor) Stem Cells	15

Adult (and Progenitor) ...(Continued)	16
STEM CELL CLASSIFICATION BASED ON DIFFERENTIATION POTENTIAL	
17	
Pluripotent Stem Cell Differentiation Potential	17
Multipotent Stem Cell Differentiation Potential	18
Unipotent Stem Cell Differentiation Potential	18
TABLE 2 STEM CELL CLASSIFICATION BASED ON DIFFERENTIATION POTENTIAL	18
DYNAMICALLY EVOLVING AREAS IN STEM CELL BIOLOGY	18
CLONAL STEM CELLS LINES IN NONHUMAN PRIMATES	18
EMBRYONIC STEM CELL LINES DERIVED FROM INNER CELL MASS OF VIABLE EMBRYOS	19
STEM CELLS FROM NEONATAL FLUID	20
ADULT STEM SOURCING/NICHES	20
Adult Stem Sourcing/Niches (Continued)	21
TABLE 3 ADULT STEM CELL TYPES AND POTENTIAL TISSUE SOURCES	
22	
DISEASE-SPECIFIC EMBRYONIC STEM CELL LINES	22
ADULT STEM CELL REPROGRAMMING	23
PERSONALIZED HEALTH CARE	24
CELL-BASED THERAPEUTICS	25
Using Embryonic-derived Stem Cells	25
Using Adult/Progenitor-derived Stem Cells	25
ENGINEERED TISSUE FOR TRANSPLANTATION	26
Using Embryonic-derived Stem Cells	26
Using Adult Stem Cells (and Progenitor Cells)	26
THERAPEUTIC STEM CELL BANKING	27
STEM-CELL-BASED BIOMEDICAL RESEARCH	27
MARKETS FOR STEM-CELL-BASED CELLULAR THERAPEUTICS	28
HEALTH CARE NEED AND THE APPLICATION OF STEM CELLS	28
Cardiovascular System-related Clinical Stem Cell Applications	29
Nervous System-related Clinical Stem Cell Applications	29
Skeletal/Muscular System-related Clinical Stem Cell Applications	29
Whole Organ (Tissue) System-related Clinical Stem Cell Applications	30
Stem-cell-related Cancer and Clinical Applications	30
Infectious Disease/Cancer (General) and Clinical Applications	31
GOVERNMENT REGULATIONS AND THE USE OF STEM CELLS IN RESEARCH AND THERAPEUTIC APPLICATIONS	31
GOVERNMENT REGULATION OF THE APPLICATION OF STEM-CELL-BASED THERAPEUTICS	31
Government Regulation of...(Continued)	32
GOVERNMENT REGULATION OF THE APPLICATION OF STEM-CELL-BASED RESEARCH	33
TABLE 4 THE NATIONAL INSTITUTES OF HEALTH STEM CELL RESEARCH FUNDING, 2004-2009 (\$ MILLIONS)	33
TABLE 4 (CONTINUED)	34

FIGURE 2 THE NATIONAL INSTITUTES OF HEALTH HUMAN STEM CELL RESEARCH FUNDING, 2004-2009 (\$ MILLIONS)	34
TABLE 5 THE NATIONAL INSTITUTES OF HEALTH HUMAN EMBRYONIC STEM CELL REGISTRY	35
TABLE 5 (CONTINUED)	36
TABLE 6 STATES FUNDING STEM-CELL-RELATED RESEARCH	37
FUTURE IMPACT OF STEM CELLS ON UNMET HEALTH CARE NEED	38
FUTURE IMPACT OF STEM ...(CONTINUED)	39
STEM CELL TECHNOLOGY IN THE REGENERATIVE MEDICINE MARKET	40
TABLE 7 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN REGENERATIVE MEDICINE, THROUGH 2012 (\$ MILLIONS)	41
FIGURE 3 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN REGENERATIVE MEDICINE, 2005-2012 (\$ MILLIONS)	41
INTRODUCTION TO STEM CELLS TECHNOLOGY IN REGENERATIVE MEDICINE MARKET	41
STEM CELLS IN CELLULAR THERAPEUTICS	42
Stem Cells in Cellular Therapeutics (Continued)	43
Stem Cells in Cellular Therapeutics (Continued)	44
FIGURE 4 FLOW DIAGRAM OF PROCESS USING STEM CELLS IN CELLULAR THERAPEUTICS	45
Stem Cells in Cellular Therapeutics (Continued)	46
TABLE 8 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN CELL-BASED THERAPEUTICS FOR HUMAN ADULT AND EMBRYONIC STEM CELLS, THROUGH 2012 (\$ MILLIONS)	47
FIGURE 5 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN CELL-BASED THERAPEUTICS FOR HUMAN ADULT AND EMBRYONIC STEM CELLS, 2005-2012 (\$ MILLIONS)	48
Stem Cells in Cellular Therapeutics towards Engineering Tissue in Vitro for Transplantation	48
Stem Cells in Cellular Therapeutics ...(Continued)	49
Stem Cells in Cellular Therapeutics ...(Continued)	50
FIGURE 6 FLOW DIAGRAM OF PROCESS USING STEM CELLS IN ENGINEERING TISSUE FOR TRANSPLANTATION	51
THERAPEUTIC STEM CELL BANKING	51
FIGURE 7 FLOW DIAGRAM FOR PROCESS OF THERAPEUTIC BANKING OF STEM CELLS	52
Therapeutic Stem Cell Banking (Continued)	53
TABLE 9 PROJECTED U.S. GROWTH TREND FOR THERAPEUTIC STEM CELL BANKING, THROUGH 2012 (\$ MILLIONS)	54
FIGURE 8 PROJECTED U.S. GROWTH TREND FOR THERAPEUTIC STEM CELL BANKING, 2005-2012 (\$ MILLIONS)	54
INTRODUCTION TO STEM CELLS TECHNOLOGY IN THERAPEUTIC-RELATED RESEARCH	54
STEM CELL TECHNOLOGY IN CELL-BASED ASSAYS AND DIAGNOSTIC RESEARCH APPLICATIONS	55

TABLE 10 PROJECTED U.S. GROWTH TREND FOR STEM-CELL-RELATED THERAPEUTIC RESEARCH (\$ MILLIONS)	56
FIGURE 9 PROJECTED U.S. GROWTH TREND FOR STEM-CELL-RELATED THERAPEUTIC RESEARCH, 2005-2012 (\$ MILLIONS)	56
THERAPEUTIC STEM-CELL-RELATED RESEARCH SUPPORT	57
TABLE 11 PROJECTED U.S. GROWTH TREND FOR STEM-CELL-RELATED CELL-BASED ASSAYS/DIAGNOSTICS THERAPEUTIC RESEARCH BY SEGMENT, THROUGH 2012 (\$ MILLIONS)	58
FIGURE 10 PROJECTED U.S. GROWTH TREND FOR STEM-CELL-RELATED CELL-BASED ASSAYS/DIAGNOSTICS THERAPEUTIC RESEARCH BY SEGMENT, 2005-2012 (\$ MILLIONS)	58
FACTORS DRIVING AND INHIBITING APPLICATION OF STEM CELL TECHNOLOGY	59
Factors Driving and Inhibiting ...(Continued)	60
Factors Driving and Inhibiting ...(Continued)	61
Factors Driving and Inhibiting ...(Continued)	62
TABLE 12 FACTORS DRIVING AND INHIBITING THE APPLICATION OF STEM-CELL-BASED THERAPEUTICS	63
MARKETS BY TYPES OF APPLICATIONS	64
INTRODUCTION TO STEM-CELL-THERAPEUTIC-BASED APPLICATIONS	64
STEM CELL APPLICATIONS: REGENERATIVE MEDICINE	64
Stem Cell Applications Specifically by Tissue Type	64
Stem Cell Applications Specifically by Organ System Type	65
Stem Cell Applications in Infectious Disease, Genetic Disorders, and Cancer-related	66
TABLE 13 STEM CELL TECHNOLOGY APPLICATIONS IN REGENERATIVE MEDICINE	67
STEM CELL APPLICATIONS IN RESEARCH AND DEVELOPMENT	67
Stem Cell Applications in Academic Research	67
Stem Cell Applications in Biotechnology and Medical Device Research	68
Stem Cells in Pharmaceutical Research	69
TABLE 14 STEM CELL TECHNOLOGY AREAS OF APPLICATION WITHIN THE LIFE SCIENCES	70
STEM CELL TECHNOLOGY AND DEVELOPMENT	71
STEM CELL PRODUCTION	71
STEM CELL ACQUISITION	71
CHARACTERIZATION AND EXPANSION	72
MAINTENANCE AND STORAGE	73
FIGURE 11 FLOW DIAGRAM FOR PROCESS OF STEM CELL PRODUCTION	74
STEM CELL PRODUCTION ECONOMICS	74
STEM CELL PRODUCTION ECONOMICS (CONTINUED)	75
NOVEL STEM CELL PRODUCTION DEVELOPMENTS	76
ISOLATION AND ENGINEERING	76

NOVEL DEVELOPMENTS IN THE PRODUCTION OF ADULT STEM CELLS	
77	
NOVEL DEVELOPMENTS IN THE PRODUCTION OF EMBRYONIC STEM CELLS	
78	
Novel Developments in the Production ... (Continued)	79
LEADERS IN STEM CELL RESEARCH DEVELOPMENT	80
ACADEMIC RESEARCH AND DEVELOPMENT LEADERS	80
Academic Stem Cell Research and Development Scientists	81
George Q. Daley, MD, Ph.D.	81
Kevin Eggan, Ph.D.	81
Doug Melton, Ph.D.	81
Amy Wagers, Ph.D.	82
Robert Langer, Sc.D.	82
Irving Weissman, MD	82
Stuart Orkin, MD	82
Joseph Vacanti, MD	83
Kenneth Chien, MD, Ph.D.	83
Rudolf Jaenisch, MD	84
Daniel Tenen, MD	84
Konrad Hochedlinger, Ph.D.	84
Paul Matsudaira, Ph.D.	85
Anthony Atala, MD	85
Elaine Fuchs, Ph.D.	85
David J. Mooney, Ph.D.	86
James A. Thomson, Ph.D.	86
Shinya Yamanaka, MD, Ph.D.	86
Kacey G. Marra, Ph.D.	87
Gordon Keller, Ph.D.	87
Johnny Huard, Ph.D.	87
Hans Keirstead, Ph.D.	88
Shoukhrat Mitalipov, Ph.D.	88
Gordon Keller, Ph.D.	89
TABLE 15 HIGHLIGHTED STEM CELL RESEARCH PUBLICATIONS, 2005-2008	
89	
TABLE 15 (CONTINUED)	90
TABLE 15 (CONTINUED)	91
INDUSTRY RESEARCH AND DEVELOPMENT LEADERS	91
TECHNOLOGY PATENT ANALYSIS	92
GENERAL TRENDS	92
TABLE 16 STEM CELL PATENT TRENDS, 2000-2008	93
FIGURE 12 STEM CELL PATENT TRENDS, 2000-2008	93
TRENDS BY COUNTRY	93
TABLE 17 STEM CELL PATENT COUNTRY CODES, 2000-2008	94
TABLE 18 STEM CELL PATENT TRENDS BY COUNTRY, 2000-2008	94
TABLE 19 STEM CELL PATENT TRENDS BY COUNTRY OF PATENTS, 2000-2008 (%)	95

FIGURE 13 STEM CELL PATENT TRENDS BY COUNTRY % OF PATENTS, 2000-2008 (%)	95
TRENDS BY COMPANIES	96
TABLE 20 STEM CELL PATENT TRENDS BY COMPANIES ASSIGNED TWO OR MORE PATENTS, 2000-2008	96
STEM CELL INDUSTRY STRUCTURE	97
DRIVING FORCES IN STEM-CELL-BASED INDUSTRIES	97
DRIVING FORCES IN THE HEALTH CARE MARKET	97
BIOTECHNOLOGY	98
PHARMACEUTICAL	99
COMPETITIVE ADVANTAGES IN STEM-CELL-BASED INDUSTRIES	100
TECHNOLOGY DEVELOPMENT AND UTILIZATION	100
COST OF NEW PRODUCT DEVELOPMENT, MANUFACTURING, AND LAUNCH	101
Cost of New Product Development, ... (Continued)	102
MARKET POSITIONING AND CAPTURE	103
Market Positioning and Capture (Continued)	104
Market Positioning and Capture (Continued)	105
IMPORTANT SHIFTS IN INDUSTRY	106
CONTINUOUSLY EVOLVING TECHNOLOGICAL BASE	106
Continuously Evolving Technological Base (Continued)	107
EFFECTS OF FLUCTUATIONS IN FEDERAL GOVERNMENT AND FOOD AND DRUG ADMINISTRATION REGULATORY FACTORS	108
TABLE 21 RESTRICTIONS ON STEM CELL RESEARCH BY STATE	109
TABLE 21 (CONTINUED)	110
TABLE 21 (CONTINUED)	111
TABLE 21 (CONTINUED)	112
TABLE 21 (CONTINUED)	113
TABLE 21 (CONTINUED)	114
TABLE 21 (CONTINUED)	115
Food and Drug Administration Approval Requirements for Implementation of Stem-cell-based Therapeutics	115
STAGE OF STEM CELL LIFE CYCLE	116
TABLE 22 TOTAL NUMBER OF STEM CELL CLINICAL TRIALS, 2000-2008	117
FIGURE 14 TOTAL NUMBER OF STEM CELL CLINICAL TRIALS, 2000-2008	117
TABLE 23 TOTAL NUMBER OF STEM CELL CLINICAL TRIALS FUNDED BY INDUSTRY, 2000-2008	118
FIGURE 15 TOTAL NUMBER OF STEM CELL CLINICAL TRIALS FUNDED BY INDUSTRY, 2000-2008	118
TABLE 24 STEM CELL CLINICAL TRIALS RELATED TO CANCER (PERIPHERAL BLOOD/BONE MARROW TRANSPLANTATION), 2000-2008 (%)	119

FIGURE 16 STEM CELL CLINICAL TRIALS RELATED TO CANCER (PERIPHERAL BLOOD/BONE MARROW TRANSPLANTATION), 2000-2008 (%)	
120	
IMPACT ON EXISTING HEALTH CARE MARKET MAY BE SIGNIFICANT	121
MAJOR STEM CELL COMPANIES	122
MAJOR STEM CELL MARKETS	123
Stem Cell Market Segmentation	123
Stem Cell Market Forces	124
Stem Cell Market Forces (Continued)	125
GENERAL STEM CELL TECHNOLOGY ISSUES	126
STEM CELL TECHNOLOGY ISSUES BY TECHNOLOGY TYPE	127
Embryonic Stem Cells	127
Adult Stem Cells	128
STEM CELL COMPANIES PERCENT MARKET SHARE	128
Stem Cell Companies Percent Market Share (Continued)	129
TABLE 25 MARKET SHARE OF STEM CELL THERAPEUTICS (AND BANKING) COMPANIES, 2005-2007 (%)	130
COMPANY PROFILES	131
AASTROM BIOSCIENCES, INC.	131
TABLE 26 AASTROM BIOSCIENCES, INC. STEM CELL CLINICAL TRIALS	
131	
TABLE 26 (CONTINUED)	132
TABLE 27 AASTROM BIOSCIENCES, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	132
ALDAGEN, INC.	133
TABLE 28 ALDAGEN, INC. STEM CELL CLINICAL TRIALS	133
TABLE 29 ALDAGEN, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	133
ADVANCED CELL TECHNOLOGY, INC.	134
TABLE 30 ADVANCED CELL TECHNOLOGY, INC. STEM CELL CLINICAL TRIALS	134
TABLE 31 ADVANCED CELL TECHNOLOGY, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	134
TABLE 31 (CONTINUED)	135
ARTERIOCYTE, INC.	135
TABLE 32 ARTERIOCYTE, INC. STEM CELL CLINICAL TRIALS	136
ATHERSYS, INC.	136
BD BIOSCIENCES	136
BIO-MATRIX SCIENTIFIC GROUP, INC.	137
BIOE	137
TABLE 33 BIOE STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	
138	
BIOHEART, INC.	138
TABLE 34 BIOHEART, INC. STEM CELL CLINICAL TRIALS	139
TABLE 35 BIOHEART, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	139

CELGENE CORP.	139
CELLERANT THERAPEUTICS, INC.	140
TABLE 36 CELLERANT THERAPEUTICS, INC. STEM CELL CLINICAL TRIALS	140
TABLE 37 CELLERANT THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	140
CELLULAR DYNAMICS INTERNATIONAL, INC.	141
COGNATE BIOSERVICES, INC.	141
TABLE 38 COGNATE BIOSERVICES, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	142
CRYO-CELL INTERNATIONAL, INC.	142
CYTOMATRIX, LLC	142
TABLE 39 CYTOMATRIX, LLC STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	143
CYTORI THERAPEUTICS, INC.	143
TABLE 40 CYTORI THERAPEUTICS, INC. STEM CELL CLINICAL TRIALS	144
TABLE 41 CYTORI THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	144
TABLE 41 (CONTINUED)	145
ENDGENITOR TECHNOLOGIES, INC.	145
FORTICELL BIOSCIENCE, INC.	145
TABLE 42 FORTICELL BIOSCIENCE, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	146
GERON CORP	146
TABLE 43 GERON CORP STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	147
HEALTHUNIVERSE, INC.	147
TABLE 44 HEALTHUNIVERSE, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	148
INTERNATIONAL STEM CELL CORPORATION	148
INVITROGEN CORPORATION	149
MATTEK CORPORATION	149
TABLE 45 MATTEK CORP STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	149
MEDISTEM LABORATORIES, INC.	150
TABLE 46 MEDISTEM LABORATORIES, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	150
MEDRA, INC.	151
MILLIPORE	151
MORPHOGENESIS, INC.	151
TABLE 47 MORPHOGENESIS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	152
MG BIOTHERAPEUTICS, LLC	152
MORAGA BIOTECHNOLOGY CORPORATION	152
NEOSTEM, INC.	153

TABLE 48 NEOSTEM, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	154
NEURALSTEM, INC.	154
TABLE 49 NEURALSTEM, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	155
NEUROGENERATION	155
NEURONYX, INC.	155
TABLE 50 NEURONYX, INC. STEM CELL CLINICAL TRIALS	156
TABLE 51 NEURONYX, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	156
NUTECH MEDICAL, INC.	156
NOVOCELL, INC.	157
TABLE 52 NOVOCELL, INC. STEM CELL CLINICAL TRIALS	157
TABLE 53 NOVOCELL, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	158
OPEXA THERAPEUTICS, INC.	158
TABLE 54 OPEXA THERAPEUTICS, INC. STEM CELL CLINICAL TRIALS	158
ORGANOGENESIS, INC.	159
TABLE 55 ORGANOGENESIS, INC. STEM CELL CLINICAL TRIALS	159
TABLE 56 ORGANOGENESIS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	160
OSIRIS THERAPEUTICS, INC.	160
TABLE 57 OSIRIS THERAPEUTICS, INC. STEM CELL CLINICAL TRIALS	160
TABLE 57 (CONTINUED)	161
TABLE 58 OSIRIS THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	161
PHARMASTEM THERAPEUTICS, INC.	162
TABLE 59 PHARMASTEM THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	162
PRIMEGEN BIOTECH, LLC	162
PROGENITOR CELL THERAPY, LLC	163
REGENETECH, INC.	163
TABLE 60 REGENETECH, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	164
SANERON CCEL THERAPEUTICS, INC.	164
STEM CELL INNOVATIONS	164
TABLE 61 STEM CELL INNOVATIONS STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	165
STEM CELLS, INC.	165
TABLE 62 STEM CELLS, INC. STEM CELL CLINICAL TRIALS	165
TABLE 63 STEM CELLS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	166
STEM CELL THERAPY INTERNATIONAL CORP.	166
STEMCELL PHARMA, INC.	167
STEMCYTE, INC.	167
STEMEDICA CELL TECHNOLOGIES, INC.	167

TENGION, INC.	168
TABLE 64 TENGION, INC. STEM CELL CLINICAL TRIALS	168
THERADIGM, INC.	169
TABLE 65 THERADIGM, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	169
THERMOGENESIS CORP.	169
VESTA THERAPEUTICS, INC.	170
TABLE 66 VESTA THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	170
VIACELL, INC.	171
TABLE 67 VIACELL, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	171
VIACORD	171
VISTAGEN THERAPEUTICS, INC.	172
TABLE 68 VISTAGEN THERAPEUTICS, INC. STEM CELL CLINICAL TRIALS	172
TABLE 69 VISTAGEN THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	172
VITRO DIAGNOSTICS, INC.	172
VITRO DIAGNOSTICS, INC. (CONTINUED)	173
INTERNATIONAL ASPECTS OF REGENERATIVE MEDICINE/STEM CELL MARKET	174
INTERNATIONAL ASPECTS OF...	174
TABLE 70 LEADING GLOBAL REGENERATIVE MEDICINE/STEM CELL COMPANIES	175
REFERENCES	176
REFERENCES	176
REFERENCES (CONTINUED)	177
REFERENCES (CONTINUED)	178
REFERENCES (CONTINUED)	179
REFERENCES (CONTINUED)	180
REFERENCES (CONTINUED)	181
REFERENCES (CONTINUED)	182
REFERENCES (CONTINUED)	183
REFERENCES (CONTINUED)	184
REFERENCES (CONTINUED)	185
APPENDIX A — ABBREVIATIONS	186
APPENDIX B — GLOSSARY	187
APPENDIX B — GLOSSARY	187
APPENDIX B — GLOSSARY (CONTINUED)	188
APPENDIX B — GLOSSARY (CONTINUED)	189
APPENDIX C — STEM CELL PATENTS, 2000-2008	190
TABLE 71 STEM CELL PATENTS BETWEEN THE YEARS 2000 AND 2008	190
TABLE 71 (CONTINUED)	191
TABLE 71 (CONTINUED)	192
TABLE 71 (CONTINUED)	193

TABLE 71 (CONTINUED)	194
TABLE 71 (CONTINUED)	195
TABLE 71 (CONTINUED)	196
TABLE 71 (CONTINUED)	197
TABLE 71 (CONTINUED)	198
TABLE 71 (CONTINUED)	199
TABLE 71 (CONTINUED)	200
TABLE 71 (CONTINUED)	201
TABLE 71 (CONTINUED)	202
TABLE 71 (CONTINUED)	203
TABLE 71 (CONTINUED)	204
TABLE 71 (CONTINUED)	205
TABLE 71 (CONTINUED)	206
TABLE 71 (CONTINUED)	207

SUMMARY TABLE U.S. MARKET FOR STEM CELLS IN REGENERATIVE
 MEDICINE REVENUE, THROUGH 2012 (\$ MILLIONS) XXIV

TABLE 1 DERIVATION OF HUMAN TISSUE TYPES DURING DEVELOPMENT	3
TABLE 2 STEM CELL CLASSIFICATION BASED ON DIFFERENTIATION POTENTIAL	18
TABLE 3 ADULT STEM CELL TYPES AND POTENTIAL TISSUE SOURCES	22
TABLE 4 THE NATIONAL INSTITUTES OF HEALTH STEM CELL RESEARCH FUNDING, 2004-2009 (\$ MILLIONS)	33
TABLE 5 THE NATIONAL INSTITUTES OF HEALTH HUMAN EMBRYONIC STEM CELL REGISTRY	35
TABLE 6 STATES FUNDING STEM-CELL-RELATED RESEARCH	37
TABLE 7 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN REGENERATIVE MEDICINE, THROUGH 2012 (\$ MILLIONS)	41
TABLE 8 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN CELL-BASED THERAPEUTICS FOR HUMAN ADULT AND EMBRYONIC STEM CELLS, THROUGH 2012 (\$ MILLIONS)	47
TABLE 9 PROJECTED U.S. GROWTH TREND FOR THERAPEUTIC STEM CELL BANKING, THROUGH 2012 (\$ MILLIONS)	54
TABLE 10 PROJECTED U.S. GROWTH TREND FOR STEM-CELL-RELATED THERAPEUTIC RESEARCH (\$ MILLIONS)	56
TABLE 11 PROJECTED U.S. GROWTH TREND FOR STEM-CELL-RELATED CELL-BASED ASSAYS/DIAGNOSTICS THERAPEUTIC RESEARCH BY SEGMENT, THROUGH 2012 (\$ MILLIONS)	58
TABLE 12 FACTORS DRIVING AND INHIBITING THE APPLICATION OF STEM-CELL-BASED THERAPEUTICS	63
TABLE 13 STEM CELL TECHNOLOGY APPLICATIONS IN REGENERATIVE MEDICINE	67

TABLE 14 STEM CELL TECHNOLOGY AREAS OF APPLICATION WITHIN THE LIFE SCIENCES	70
TABLE 15 HIGHLIGHTED STEM CELL RESEARCH PUBLICATIONS, 2005-2008	89
TABLE 16 STEM CELL PATENT TRENDS, 2000-2008	93
TABLE 17 STEM CELL PATENT COUNTRY CODES, 2000-2008	94
TABLE 18 STEM CELL PATENT TRENDS BY COUNTRY, 2000-2008	94
TABLE 19 STEM CELL PATENT TRENDS BY COUNTRY OF PATENTS, 2000-2008 (%)	95
TABLE 20 STEM CELL PATENT TRENDS BY COMPANIES ASSIGNED TWO OR MORE PATENTS, 2000-2008	96
TABLE 21 RESTRICTIONS ON STEM CELL RESEARCH BY STATE	109
TABLE 22 TOTAL NUMBER OF STEM CELL CLINICAL TRIALS, 2000-2008	117
TABLE 23 TOTAL NUMBER OF STEM CELL CLINICAL TRIALS FUNDED BY INDUSTRY, 2000-2008	118
TABLE 24 STEM CELL CLINICAL TRIALS RELATED TO CANCER (PERIPHERAL BLOOD/BONE MARROW TRANSPLANTATION), 2000-2008 (%)	119
TABLE 25 MARKET SHARE OF STEM CELL THERAPEUTICS (AND BANKING) COMPANIES, 2005-2007 (%)	130
TABLE 26 AASTROM BIOSCIENCES, INC. STEM CELL CLINICAL TRIALS	131
TABLE 27 AASTROM BIOSCIENCES, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	132
TABLE 28 ALDAGEN, INC. STEM CELL CLINICAL TRIALS	133
TABLE 29 ALDAGEN, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	133
TABLE 30 ADVANCED CELL TECHNOLOGY, INC. STEM CELL CLINICAL TRIALS	134
TABLE 31 ADVANCED CELL TECHNOLOGY, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	134
TABLE 32 ARTERIOCYTE, INC. STEM CELL CLINICAL TRIALS	136
TABLE 33 BIOE STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	138
TABLE 34 BIOHEART, INC. STEM CELL CLINICAL TRIALS	139
TABLE 35 BIOHEART, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	139
TABLE 36 CELLERANT THERAPEUTICS, INC. STEM CELL CLINICAL TRIALS	140
TABLE 37 CELLERANT THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	140
TABLE 38 COGNATE BIOSERVICES, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	142
TABLE 39 CYTOMATRIX, LLC STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	143

TABLE 40	CYTORI THERAPEUTICS, INC. STEM CELL CLINICAL TRIALS	
		144
TABLE 41	CYTORI THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	144
TABLE 42	FORTICELL BIOSCIENCE, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	146
TABLE 43	GERON CORP STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	147
TABLE 44	HEALTHUNIVERSE, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	148
TABLE 45	MATTEK CORP STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	149
TABLE 46	MEDISTEM LABORATORIES, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	150
TABLE 47	MORPHOGENESIS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	152
TABLE 48	NEOSTEM, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	154
TABLE 49	NEURALSTEM, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	155
TABLE 50	NEURONYX, INC. STEM CELL CLINICAL TRIALS	156
TABLE 51	NEURONYX, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	156
TABLE 52	NOVOCELL, INC. STEM CELL CLINICAL TRIALS	157
TABLE 53	NOVOCELL, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	158
TABLE 54	OPEXA THERAPEUTICS, INC. STEM CELL CLINICAL TRIALS	158
TABLE 55	ORGANOGENESIS, INC. STEM CELL CLINICAL TRIALS	159
TABLE 56	ORGANOGENESIS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	160
TABLE 57	OSIRIS THERAPEUTICS, INC. STEM CELL CLINICAL TRIALS	160
TABLE 58	OSIRIS THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	161
TABLE 59	PHARMASTEM THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	162
TABLE 60	REGENETECH, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	164
TABLE 61	STEM CELL INNOVATIONS STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	165
TABLE 62	STEM CELLS, INC. STEM CELL CLINICAL TRIALS	165
TABLE 63	STEM CELLS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	166
TABLE 64	TENGION, INC. STEM CELL CLINICAL TRIALS	168
TABLE 65	THERADIGM, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	169

TABLE 66 VESTA THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	170
TABLE 67 VIACELL, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	171
TABLE 68 VISTAGEN THERAPEUTICS, INC. STEM CELL CLINICAL TRIALS	172
TABLE 69 VISTAGEN THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED	172
TABLE 70 LEADING GLOBAL REGENERATIVE MEDICINE/STEM CELL COMPANIES	175
TABLE 71 STEM CELL PATENTS BETWEEN THE YEARS 2000 AND 2008	190

SUMMARY FIGURE U.S. MARKET FOR STEM CELLS IN REGENERATIVE MEDICINE REVENUE, 2005-2012 (\$ MILLIONS)	XXIV
---	------

FIGURE 1 FLOW DIAGRAM OF HUMAN DEVELOPMENT PROCESS	4
FIGURE 2 THE NATIONAL INSTITUTES OF HEALTH HUMAN STEM CELL RESEARCH FUNDING, 2004-2009 (\$ MILLIONS)	34
FIGURE 3 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN REGENERATIVE MEDICINE, 2005-2012 (\$ MILLIONS)	41
FIGURE 4 FLOW DIAGRAM OF PROCESS USING STEM CELLS IN CELLULAR THERAPEUTICS	45
FIGURE 5 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN CELL-BASED THERAPEUTICS FOR HUMAN ADULT AND EMBRYONIC STEM CELLS, 2005-2012 (\$ MILLIONS)	48
FIGURE 6 FLOW DIAGRAM OF PROCESS USING STEM CELLS IN ENGINEERING TISSUE FOR TRANSPLANTATION	51
FIGURE 7 FLOW DIAGRAM FOR PROCESS OF THERAPEUTIC BANKING OF STEM CELLS	52
FIGURE 8 PROJECTED U.S. GROWTH TREND FOR THERAPEUTIC STEM CELL BANKING, 2005-2012 (\$ MILLIONS)	54
FIGURE 9 PROJECTED U.S. GROWTH TREND FOR STEM-CELL-RELATED THERAPEUTIC RESEARCH, 2005-2012 (\$ MILLIONS)	56
FIGURE 10 PROJECTED U.S. GROWTH TREND FOR STEM-CELL-RELATED CELL-BASED ASSAYS/DIAGNOSTICS THERAPEUTIC RESEARCH BY SEGMENT, 2005-2012 (\$ MILLIONS)	58
FIGURE 11 FLOW DIAGRAM FOR PROCESS OF STEM CELL PRODUCTION	74
FIGURE 12 STEM CELL PATENT TRENDS, 2000-2008	93
FIGURE 13 STEM CELL PATENT TRENDS BY COUNTRY % OF PATENTS, 2000-2008 (%)	95
FIGURE 14 TOTAL NUMBER OF STEM CELL CLINICAL TRIALS, 2000-2008	117
FIGURE 15 TOTAL NUMBER OF STEM CELL CLINICAL TRIALS FUNDED BY INDUSTRY, 2000-2008	118

FIGURE 16 STEM CELL CLINICAL TRIALS RELATED TO CANCER
(PERIPHERAL BLOOD/BONE MARROW TRANSPLANTATION), 2000-2008 (%)
120